A Phase IB/II Multi-Arm Study With Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Phase of Trial: Phase I/II
Latest Information Update: 11 May 2017
At a glance
- Drugs Venetoclax (Primary) ; Cobimetinib; Idasanutlin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 11 Apr 2017 Planned End Date changed from 1 Sep 2019 to 31 Jul 2019.
- 01 Aug 2016 Planned End Date changed from 1 Dec 2017 to 1 Sep 2019.
- 01 Jul 2016 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.